Transcatheter Edge-to-Edge Repair for Tricuspid Valve Regurgitation (T-TEER)

Medicare covers transcatheter edge-to-edge repair for tricuspid regurgitation only when furnished per an FDA market-authorized indication and performed within a CMS-approved Coverage with Evidence Development (CED) study. Coverage requires symptomatic TR despite optimal medical therapy, care by a specified multidisciplinary heart team, CED protocols with defined outcomes (including ≥24 months follow-up), an active comparator, subgroup analyses, adherence to AHRQ scientific standards, and required protocol registration, reporting, and data-sharing documentation.

"T-TEER is covered when furnished according to an FDA market-authorized indication and the patient has symptomatic tricuspid regurgitation despite optimal medical therapy, with tricuspid valve repai..."

Sign up to see full coverage criteria, indications, and limitations.